Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data

(2011) Leonid Kagan et al.   AAPS Journal

Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009)

(2010) P. Gershkovich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model

(2010) Ellen K. Wasan et al.   PLoS Neglected Tropical Diseases

The reformulation of Amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis

(2009) Sheila J Thornton et al.   Expert Opinion on Drug Delivery

Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

(2009) Ellen K. Wasan et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

(2009) P. Gershkovich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis

(2009) Kishor M. Wasan et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of Brazilian copaiba oils on Leishmania amazonensis

(2008) Adriana O. Santos et al.   JOURNAL OF ETHNOPHARMACOLOGY

Amphotericin B Formulations and Drug Targeting

(2007) J.J. Torrado et al.   JOURNAL OF PHARMACEUTICAL SCIENCES